Kudos to Catherine Polizzi on Her Induction into the LMG Life Sciences Hall of Fame

 

Palo Alto partner Catherine Polizzi has been described as innovative, pragmatic, and incisive when it comes to helping emerging and established companies navigate the world of patents and portfolios. Therefore, it’s only fitting that LMG Life Sciences inducted Catherine into its Hall of Fame on September 12, 2018 in recognition of her exceptional achievements in the life sciences field.

Each year, LMG Life Sciences conducts a survey that measures feedback from peers, clients, firms, and publicly available information to be published in their annual editorial guide. From those results, the top life sciences attorneys from across the United States are selected and honored during an award ceremony in New York City.

Catherine is already a recognized leader among her peers. She has been engaged in some of the most high-profile, complex matters in the pharma and biotech sectors. Her innovative work in IP strategy, portfolio development, risk management, and mergers and acquisitions has helped a variety of companies – from start-ups to multi-billion dollar corporations. Where she shines is in her innovative work helping to develop and protect life-saving therapies, breakthrough drugs, and novel technologies.

Through strategic portfolio development and IP integration, she has provided value across many therapeutic areas such as cancer immunotherapy, autoimmune diseases, infectious diseases, and Alzheimer’s disease. Catherine also has significant experience in wide-ranging technologies such as biologics, genetic screening, nanotechnologies, and precision medicine.

Her deep understanding of how patents fit into the larger business model and strategy, has given her an edge in representing large-scale transactions, including a $14 billion acquisition by Pfizer of client Medivation, a previous $225 million Pfizer investment in Medivation, and Myriad Genetics’ $375 million acquisition of Counsyl, Inc.

Catherine’s biggest achievement over the last year was being involved in Celgene’s acquisition of Juno Therapeutics, where she acted as the strategic architect of Juno’s patent portfolio, helping to drive the $9 billion valuation of the acquisition.

Chambers USA noted that Catherine “maintains a strong reputation for her capabilities advising biotechnology clients on portfolio management and other IP matters,” while clients find her “refreshing [because of] her tactical advice.

This year’s Hall of Fame designation marks the third recognition for Catherine from Legal Media Group, a market-leading research and publishing firm for the legal community. She was named Patent Strategy & Management Attorney of the Year – California in 2017, received the 2013 Americas Women in Business Law Award for life sciences, and has earned the rank of Life Sciences Star every year, since 2012.